Furen Pharmaceutical Group Industry Co. Ltd. provided earnings guidance for the year 2017. According to preliminary statistics of its financial department, the company predicts that the net profit owned by shareholders of the company in 2017 will increase by between RMB 330 million and RMB 360 million, with an increase of between 1,868.98% and 2,038.89% compared with the same period of the year before (excluding influence of retroactive restatement of merger of enterprises under same control). The net profit belonging to shareholders of the company after excluding extraordinary profit and loss will increase by between RMB 2 million and RMB 10 million, with an increase of between 10.76% and 53.82% compared with the same period of the year before (excluding influence of retroactive restatement of merger of enterprises under same control). Taking merger of enterprises under same control into account, after retroactive restatement of the financial statement of the same period of the previous year, the Company predicted that the net profit owned by shareholders of the company in 2017 will increase by between RMB 12 million and RMB 47 million, with an increase of between 3.6% and 14.13% compared with the same period of the year before (including influence of retroactive restatement of merger of enterprises under same control).